{
    "root": "302a4314-e1d6-3ce6-e063-6394a90a75a1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lapatinib",
    "value": "20250312",
    "ingredients": [
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "POVIDONE K25",
            "code": "K0KQV10C35"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "LAPATINIB DITOSYLATE",
            "code": "G873GX646R"
        }
    ],
    "indications": "lapatinib tablets indicated combination : capecitabine treatment patients advanced metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 ( her2 ) received prior therapy , including anthracycline , taxane , trastuzumab . limitations : patients disease progression trastuzumab prior initiation treatment lapatinib tablets combination capecitabine . letrozole treatment postmenopausal women hormone receptor-positive metastatic breast cancer overexpresses her2 receptor hormonal therapy indicated . lapatinib tablets combination aromatase inhibitor compared trastuzumab-containing chemotherapy regimen treatment metastatic breast cancer .",
    "contraindications": "recommended lapatinib tablets advanced metastatic breast cancer 1,250 mg ( 5 tablets ) given orally daily days 1 21 continuously combination capecitabine 2,000 mg/m 2 /day ( administered orally 2 doses approximately 12 hours apart ) days 1 14 repeating 21-day cycle . ( 2.1 ) recommended dose lapatinib tablets hormone receptor-positive , her2-positive metastatic breast cancer 1,500 mg ( 6 tablets ) given orally daily continuously combination letrozole . lapatinib tablets coadministered letrozole , recommended dose letrozole 2.5 mg daily . ( 2.1 ) lapatinib tablets taken least one hour one hour meal . however , capecitabine taken food within 30 minutes food . ( 2.1 ) lapatinib tablets taken daily . divide daily doses lapatinib tablets . ( 2.1 , 12.3 ) modify dose cardiac toxicities , severe hepatic impairment , diarrhea , cyp3a4 . ( 2.2 )",
    "warningsAndPrecautions": "lapatinib tablets available follows : 250 mg - yellow , oval , film-coated tablet , debossed “ l250 ” one side “ tv ” side contains 398 mg lapatinib ditosylate equivalent 250 mg lapatinib . tablets available bottles 150 ( ndc 42291-035-15 ) . store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . keep medications reach children .",
    "adverseReactions": "lapatinib tablets contraindicated patients known severe hypersensitivity ( e.g . , anaphylaxis ) product components .",
    "indications_original": "Lapatinib tablets are indicated in combination with:\n                  \n                     capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab.\n  \n   \n                           Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine.\n  \n   \n                     \n                  \n                  \n                     letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.\n                  \n                  Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",
    "contraindications_original": "The recommended dosage of lapatinib tablets for advanced or metastatic breast cancer is 1,250 mg (5 tablets) given orally once daily on Days 1 to 21 continuously in combination with capecitabine 2,000 mg/m 2 /day (administered orally in 2 doses approximately 12 hours apart) on Days 1 to 14 in a repeating 21-day cycle. ( 2.1 ) The recommended dose of lapatinib tablets for hormone receptor-positive, HER2-positive metastatic breast cancer is 1,500 mg (6 tablets) given orally once daily continuously in combination with letrozole. When lapatinib tablets are coadministered with letrozole, the recommended dose of letrozole is 2.5 mg once daily. ( 2.1 ) Lapatinib tablets should be taken at least one hour before or one hour after a meal. However, capecitabine should be taken with food or within 30 minutes after food. ( 2.1 ) Lapatinib tablets should be taken once daily. Do not divide daily doses of lapatinib tablets. ( 2.1 , 12.3 ) Modify dose for cardiac and other toxicities, severe hepatic impairment, diarrhea, and CYP3A4 drug interactions. ( 2.2 )",
    "warningsAndPrecautions_original": "Lapatinib tablets are available as follows:\n                  250 mg - Each yellow, oval, film-coated tablet, debossed with “L250” on one side and “TV” on the other side contains 398 mg lapatinib ditosylate equivalent to 250 mg of lapatinib. Tablets are available in bottles of 150 (NDC 42291-035-15).\n                  Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Keep this and all medications out of the reach of children.",
    "adverseReactions_original": "Lapatinib tablets are contraindicated in patients with known severe hypersensitivity (e.g., anaphylaxis) to this product or any of its components."
}